Tag: Abiomed

Abiomed gains approval for data streaming from the Impella console

The US Food and Drug Administration (FDA) has approved one-way digital data streaming during patient support from Abiomed’s Automated Impella Controller (AIC), the external...

SCAI 2020: PROTECT III shows placing Impella prior to high-risk PCI...

Data from more than 1,000 patients presented during the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Scientific Sessions (14–16 May, Eastern Time)...

Abiomed acquires novel ECMO developer Breethe

Abiomed (maker of the Impella heart pump) has acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system. A press release reports that...

COVID-19: Edwards pauses enrolment in mitral and tricuspid trials to allow...

Edwards Lifesciences has temporarily paused new enrolments in its active pivotal clinical trials of its transcatheter mitral and tricuspid therapies in response to ongoing...

ADVERTORIAL: Further data underline the critical role of Impella Heart Pumps...

Findings from an interim analysis of PROTECT III have added to the evidence for improved outcomes with Impella heart pumps in protected percutaneous coronary...
impella in preventing heart failure in stemi patients

New trial to evaluate role of Impella in preventing heart failure...

A pivotal, multicentre clinical trial is exploring the use of an Impella heart pump (Abiomed) to unload the left ventricle for 30 minutes prior...

ESC 2019: Abiomed launches Impella SmartAssist platform

At the 2019 European Society Cardiology (ESC) congress (31 August – 4 September, Paris, France), Abiomed revealed that its Impella CP with SmartAssist technology is...
impella in preventing heart failure in stemi patients

FDA approves extended duration of use for Impella 5.0 and Impella...

Abiomed has announced an expanded US Food and Drug Administration (FDA) approval for the Impella 5.0 and Impella LD heart pumps premarket approval (PMA)...

Challenges of conducting a randomised clinical trials to prove the impact...

Mechanical circulatory support is frequently used to stabilise patient haemodynamics in desperate situations of circulatory failure to increase and maintain end organ perfusion.1 Of...

CE mark for cloud-based monitoring platform Impella Connect

Abiomed has achieved the CE mark for Impella Connect, which—a press release reports—is the first-of-its kind cloud-based technology that enables secure, real-time, remote viewing...

Abiomed invests $15 million in Shockwave Medical

A press release reports that Abiomed is to invest US$15 million in Shockwave Medical and the two companies will collaborate on a training and...

AHA 2018: Pilot study paves way for future evaluation of delaying...

A pilot study comparing a strategy of left ventricular unloading with the Impella CP device (Abiomed) and delayed reperfusion (up to 30 minutes after...

TCT 2018: Use of Impella in cardiogenic shock patients associated with...

A new analysis of data from the Impella (Abiomed) Quality (IQ) Database shows a relative increase of 24% in mean survival in acute myocardial...

Abiomed receives FDA approval for Impella CP with SmartAssist and Optical...

Abiomed has received US FDA premarket approval (PMA) for its Impella CP heart pump with SmartAssist, using an optical sensor. At the forefront of innovation, according...

Abiomed receives expanded FDA approve for high-risk PCI procedures

Abiomed has received an expanded US FDA premarket approval for the Impella 2.5 and Impella CP heart pumps during elective and urgent high-risk percutaneous coronary...

FDA grants Abiomed pre-market approval for is Impella RP for right...

Abiomed has received FDA pre-market approval for its Impella RP heart pump. Culminating from five years of research, according to a press release, this...

Haemodynamic support with Impella 2.5 heart pump significantly improves survival when...

  A study published in the Journal of Interventional Cardiology indicates that the use of the Impella 2.5 heart pump (Abiomed) is associated with a...

Abiomed introduces third generation Impella CP heart pumps at SCAI 2017

Abiomed has announced the debut of the third generation Impella CP heart pump at the Annual meeting of the Society for Cardiovascular and Angiography...

Patient enrolled in STEMI DTU feasibility study

Abiomed announced today the enrolment of the first patient in the FDA approved prospective feasibility study, STEMI Door to Unloading (DTU) with Impella CP...

Study indicates that Impella heart pump reduces acute kidney injury during...

A new study published in Circulation Research finds that the use of haemodynamic support with Impella 2.5 heart pump during high-risk percutaneous coronary intervention...

FDA pre-market approval for the Impella heart pump for high-risk PCI...

Abiomed has expanded its FDA pre-market approval for Impella heart pump use in high-risk percutaneous coronary interventions (PCI) to include its Impella CP heart...

Japan approves Abiomed’s Impella 2.5 and Impella 5.0 heart pumps

Abiomed has announced that its heart pumps Impella 2.5 and Impella 5.0 have received Pharmaceuticals and Medical Devices Agency (PMDA) approval from the Japanese...